Nifty
Sensex
:
:
9915.25
32028.89
41.95 (0.42%)
124.49 (0.39%)

Pharmaceuticals & Drugs

Rating :
23/99

BSE: 524372 | NSE: ORCHIDPHAR

27.70
-0.10 (-0.36%)
21-Jul-2017 | 3:55PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 28.00
  • 28.05
  • 27.55
  • 27.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 205307
  • 56.87
  • 45.85
  • 23.90

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 247.77
  • N/A
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 3,147.41
  • N/A
  • -1.10

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.68%
  • 18.53%
  • 48.59%
  • FII
  • DII
  • Others
  • 0.36%
  • 3.69%
  • 2.15%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Standalone Figures in Rs. Crores

Description
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Jun 16
Jun 15
Var%
Net Sales
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBITDA
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Depreciation
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PBT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Sep 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Mar 06
Net Sales
873.44
1,746.61
1,947.70
1,873.60
1,781.79
2,358.76
1,296.85
1,300.96
963.82
936.63
Net Sales Growth
-49.99%
-10.32%
3.95%
5.15%
-24.46%
81.88%
-0.32%
34.98%
2.90%
 
Cost Of Goods Sold
400.96
779.03
990.12
876.31
868.89
795.29
547.45
441.36
325.11
409.00
Gross Profit
472.47
967.58
957.58
997.29
912.90
1,563.47
749.40
859.61
638.71
527.63
GP Margin
54.09%
55.40%
49.16%
53.23%
51.23%
66.28%
57.79%
66.08%
66.27%
56.33%
Total Expenditure
702.65
1,429.32
1,837.44
1,516.99
1,433.68
1,500.34
1,126.28
961.02
714.90
714.28
Power & Fuel Cost
55.28
102.19
121.72
89.14
76.80
70.58
77.55
72.90
55.12
44.45
% Of Sales
6.33%
5.85%
6.25%
4.76%
4.31%
2.99%
5.98%
5.60%
5.72%
4.75%
Employee Cost
86.81
193.82
252.70
176.41
164.73
174.48
137.46
117.14
92.45
69.64
% Of Sales
9.94%
11.10%
12.97%
9.42%
9.25%
7.40%
10.60%
9.00%
9.59%
7.44%
Manufacturing Exp.
94.33
182.40
226.41
198.70
150.32
176.73
156.91
169.37
133.37
108.34
% Of Sales
10.80%
10.44%
11.62%
10.61%
8.44%
7.49%
12.10%
13.02%
13.84%
11.57%
General & Admin Exp.
31.10
91.62
93.40
76.95
92.71
113.80
68.19
67.89
49.51
38.14
% Of Sales
3.56%
5.25%
4.80%
4.11%
5.20%
4.82%
5.26%
5.22%
5.14%
4.07%
Selling & Distn. Exp.
27.73
51.28
55.52
63.26
55.06
44.17
50.71
50.57
39.16
32.90
% Of Sales
3.17%
2.94%
2.85%
3.38%
3.09%
1.87%
3.91%
3.89%
4.06%
3.51%
Miscellaneous Exp.
6.44
28.97
97.57
36.21
25.17
125.30
88.00
41.81
20.19
32.90
% Of Sales
0.74%
1.66%
5.01%
1.93%
1.41%
5.31%
6.79%
3.21%
2.09%
1.26%
EBITDA
170.79
317.29
110.26
356.61
348.11
858.42
170.57
339.94
248.92
222.35
EBITDA Margin
19.55%
18.17%
5.66%
19.03%
19.54%
36.39%
13.15%
26.13%
25.83%
23.74%
Other Income
24.91
42.47
40.72
56.19
53.02
8.59
86.05
71.30
28.01
16.32
Interest
294.24
537.12
522.69
179.75
116.75
242.27
156.45
82.00
99.29
87.84
Depreciation
145.27
324.58
251.92
153.74
133.50
154.90
133.99
100.68
85.09
85.82
PBT
-243.82
-501.95
-623.63
79.32
150.87
469.83
-33.82
228.56
92.56
65.01
Tax
-17.25
-191.46
-12.52
-22.04
15.38
130.58
15.17
53.23
14.01
7.71
Tax Rate
5.82%
49.27%
2.19%
-29.22%
8.96%
27.79%
-44.86%
23.29%
15.14%
11.86%
PAT
-279.11
-196.51
-558.02
97.48
156.19
339.25
-48.99
175.34
78.55
57.30
PAT before Minority Interest
-279.11
-197.13
-559.99
97.48
156.19
339.25
-48.99
175.34
78.55
57.30
Minority Interest
0.00
0.62
1.97
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-31.96%
-11.25%
-28.65%
5.20%
8.77%
14.38%
-3.78%
13.48%
8.15%
6.12%
PAT Growth
-42.03%
64.78%
-672.45%
-37.59%
-53.96%
792.49%
-127.94%
123.22%
37.09%
 
Unadjusted EPS
-32.07
-26.88
-79.21
13.84
22.17
48.16
-7.14
26.63
11.93
8.87

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Sep 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Mar 06
Shareholder's Funds
49.04
329.39
379.99
1,132.30
1,069.24
937.66
633.80
664.98
485.10
775.59
Share Capital
88.96
85.26
70.45
70.44
70.44
70.44
70.44
65.85
65.82
64.62
Total Reserves
-39.92
244.12
309.53
1,061.86
998.80
867.22
563.36
599.13
419.28
710.97
Non-Current Liabilities
2,475.41
2,609.35
1,064.40
1,251.94
849.66
1,864.07
2,744.32
2,085.45
1,741.16
1,125.02
Secured Loans
2,377.54
2,493.95
901.79
1,074.15
604.06
1,035.91
1,714.11
979.56
706.56
843.27
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
625.36
901.74
990.98
942.25
201.69
Long Term Provisions
3.73
4.18
5.24
7.72
9.64
0.00
0.00
0.00
0.00
0.00
Current Liabilities
1,337.62
1,122.66
3,206.03
1,551.05
1,989.41
971.83
855.83
733.80
664.75
267.93
Trade Payables
374.27
311.15
597.40
447.00
335.16
318.21
390.10
296.23
234.55
215.62
Other Current Liabilities
285.34
112.64
1,052.57
406.96
1,005.23
293.78
369.16
359.23
388.52
22.66
Short Term Borrowings
633.79
646.64
1,524.89
647.06
489.86
0.00
0.00
0.00
0.00
0.00
Short Term Provisions
44.22
52.23
31.17
50.03
159.16
359.84
96.58
78.34
41.68
29.65
Total Liabilities
3,862.07
4,061.40
4,651.04
3,938.11
3,910.23
3,773.56
4,233.95
3,484.23
2,891.01
2,168.54
Net Block
1,636.83
1,795.20
2,583.57
2,073.88
1,741.76
1,603.31
2,007.51
1,539.95
1,105.40
990.44
Gross Block
3,005.87
3,002.15
3,772.17
3,089.68
2,613.62
2,344.63
2,695.66
2,098.12
1,563.38
1,364.17
Accumulated Depreciation
1,369.04
1,206.95
1,188.60
1,015.80
871.86
741.32
688.16
558.17
457.98
373.73
Non Current Assets
2,610.87
2,783.27
3,549.62
2,684.83
2,383.94
2,072.24
2,554.21
2,160.07
1,658.45
1,260.55
Capital Work in Progress
280.40
281.51
360.42
352.25
332.29
468.92
546.70
620.12
553.04
270.12
Non Current Investment
0.81
0.81
0.95
0.81
0.81
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
680.83
681.63
576.08
219.66
287.82
0.00
0.00
0.00
0.00
0.00
Other Non Current Assets
12.00
24.12
28.60
38.23
21.26
0.00
0.00
0.00
0.00
0.00
Current Assets
1,251.20
1,278.12
1,101.42
1,253.29
1,526.30
1,701.32
1,596.17
1,324.16
1,232.57
907.98
Current Investments
0.00
0.00
0.00
0.00
0.00
0.81
0.81
0.81
0.08
0.08
Inventories
241.85
251.93
506.24
668.73
617.63
422.64
768.25
649.15
611.61
448.15
Sundry Debtors
310.07
256.57
179.06
113.24
513.48
736.98
672.54
537.94
383.16
348.57
Cash & Bank
314.94
390.56
23.42
176.92
201.08
335.16
52.51
31.04
118.92
16.26
Other Current Assets
384.34
105.80
14.35
16.08
194.12
205.73
102.06
105.21
118.78
94.91
Short Term Loans & Adv.
267.62
273.26
378.34
278.33
184.86
201.40
96.97
101.66
115.71
92.94
Net Current Assets
-86.42
155.46
-2,104.61
-297.76
-463.11
729.49
740.34
590.36
567.82
640.05
Total Assets
3,862.07
4,061.39
4,651.04
3,938.12
3,910.24
3,773.56
4,233.96
3,484.23
2,891.02
2,168.53

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 16
Mar 15
Sep 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Mar 06
Cash From Operating Activity
212.20
-369.07
168.17
737.02
332.13
-34.32
45.90
210.29
96.02
-1.74
PBT
-296.18
-243.29
-572.51
75.44
171.57
469.83
-33.82
228.56
92.56
65.01
Adjustment
490.19
1,006.39
661.19
333.54
214.51
-557.33
199.78
132.43
189.01
175.73
Changes in Working Capital
18.19
-669.27
79.49
356.82
7.24
119.07
-117.26
-118.42
-184.38
-239.52
Cash after chg. in Working capital
212.20
93.84
168.17
765.80
393.31
31.57
48.71
242.57
97.18
1.22
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
0.00
-47.03
0.00
-28.78
-61.18
-65.89
-2.81
-32.28
-1.16
-2.96
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
-415.87
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1.46
1,333.66
-986.04
-293.05
-367.41
1,412.76
-476.97
-545.40
-477.21
-182.86
Net Fixed Assets
-2.38
848.92
-751.02
-494.66
-121.72
428.65
-504.48
-594.63
-455.46
-202.15
Net Investments
0.00
-0.47
24.72
-18.48
-6.85
-1.20
-8.55
1.89
-17.47
-26.97
Others
0.92
485.21
-259.74
220.09
-238.84
985.31
36.06
47.34
-4.28
46.26
Cash from Financing Activity
-286.36
-597.44
664.38
-480.15
-77.75
-1,076.81
431.08
247.36
485.21
181.95
Net Cash Inflow / Outflow
-75.62
367.14
-153.49
-36.17
-113.03
301.64
0.02
-87.75
104.02
-2.65
Opening Cash & Equivalents
390.56
23.42
176.92
213.09
326.13
24.49
24.47
112.22
8.20
10.85
Closing Cash & Equivalent
314.94
390.56
23.42
176.92
213.09
326.13
24.49
24.47
112.22
8.20

Financial Ratios

Consolidated /

Standalone
Description
Mar 16
Mar 15
Sep 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Mar 07
Mar 06
Book Value (Rs.)
5.51
38.63
53.94
160.74
151.79
133.11
78.11
100.98
73.70
120.03
ROA
-7.05%
-4.53%
-13.04%
2.48%
4.07%
8.47%
-1.27%
5.50%
3.10%
2.88%
ROE
-147.51%
-55.58%
-74.06%
8.86%
15.56%
45.60%
-8.06%
30.49%
12.46%
9.27%
ROCE
-0.06%
4.17%
-1.48%
8.12%
10.03%
24.70%
4.23%
13.02%
9.70%
9.30%
Fixed Asset Turnover
0.29
0.52
0.57
0.66
0.73
0.94
0.55
0.72
0.67
0.79
Receivable days
116.98
45.27
27.22
60.58
126.84
108.66
168.81
128.10
135.56
106.50
Inventory Days
101.94
78.79
109.43
124.35
105.52
91.80
197.67
175.34
196.34
162.71
Payable days
148.72
86.46
100.90
89.04
77.18
87.92
107.36
90.80
99.53
102.86
Cash Conversion Cycle
70.20
37.60
35.76
95.89
155.18
112.54
259.12
212.65
232.37
166.36
Total Debt/Equity
65.54
9.75
8.43
1.77
1.94
1.77
4.75
2.96
3.40
1.35
Interest Cover
-0.01
0.28
-0.10
1.42
2.47
2.94
0.78
3.79
1.93
1.74

News Update


  • Orchid Pharma gets ANDA approval for Aripiprazole tablet
    24th May 2017, 13:59 PM

    Aripiprazole Tablets are atypical antipsychotic indicated in the treatment symptoms of psychotic conditions

    Read More
  • Orchid Pharma gets EIR from USFDA for Tamil Nadu plant
    18th Apr 2017, 12:47 PM

    The facility was inspected by USFDA in December 2016

    Read More
  • CARE revises ratings assigned to Orchid Pharma’s bank facilities
    18th Apr 2017, 11:48 AM

    The revision in ratings assigned to the bank facilities of Orchid Pharma takes into account instances of delays in debt servicing

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.